FRCP

RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma

Retrieved on: 
Lunedì, Giugno 3, 2024
Oncology, Health, Infectious Diseases, Hospitals, Radiology, Pharmaceutical, Biotechnology, ASCO, Cancer, Mesothelioma, Lung, Multimedia, Prognosis, Patient, MPE, Peritoneum, Annual general meeting, Malignant pleural effusion, Metastasis, Trial of the century, Safety, Society, FRCP, Pericardium, Hearing, Pleural cavity, Doctor of Philosophy, MPM, Quality of life, MD–PhD, Survival, MRCP, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240603559175/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240603559175/en/
    Professor Dean Fennell, principal investigator, presents results from the Phase 1 MITOPE clinical study of a first-in-human, and potential first-in-class therapeutic, RSO-021.
  • (Photo: Business Wire)
    The Phase 1 data was presented by Professor Dean Fennell, MRCP, FRCP (MD/PhD) on behalf of all the MITOPE investigators at an oral presentation session.
  • In the 15 recruited patients safety data demonstrated weekly treatment of RSO-021 was well tolerated at 90 mg.
  • The safety and efficacy observed in the Phase 1 trial is supported by strong pre-clinical rationale” said Brian Cunniff, PhD, Chief Science Officer for RS Oncology.

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Retrieved on: 
Domenica, Giugno 2, 2024
Webcast, Fatigue, Plasma, Patient, Safety, FRCP, Royal College of Pathologists, HAE, Attack, University, Plasma kallikrein, EAACI, Pharmaceutical industry

At each dose level tested, a robust level of HAE attack rate reduction was achieved and long lasting.

Key Points: 
  • At each dose level tested, a robust level of HAE attack rate reduction was achieved and long lasting.
  • The longest attack-free interval for an individual patient post-infusion is over 26 months and ongoing.
  • Further, 100% of patients who discontinued prophylaxis treatment after NTLA-2002 remain free of chronic prophylaxis treatment.
  • A replay of the webcast will be available on Intellia’s website for at least 30 days following the call.

Chiesi Global Rare Diseases Makes Debut in the Endocrinology Landscape with Multiple Presentations at the Endocrine Society’s ENDO 2024 Meeting

Retrieved on: 
Mercoledì, Maggio 22, 2024
ENDO, Abstract, MACRO, Barrow Neurological Institute, University, Capsule, Safety, FRCP, Neurosurgery, Endocrine system, University of Arizona, FACE, Post hoc analysis, Lipodystrophy, Pharmaceutical industry

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.

Key Points: 
  • BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.
  • Attendees can visit Chiesi Global Rare Diseases product booth #526 and the medical booth #428.
  • Poster presentations include the latest data from the Chiesi Management of Acromegaly (MACRO) registry and a presentation on the Lipodystrophy Severity Scoring tool to assess the disease burden in lipodystrophy.
  • To register for ENDO 2024 and view the full meeting schedule, visit the Endocrine Society’s website here .

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Retrieved on: 
Mercoledì, Maggio 22, 2024
University of Hong Kong, Doctor of Philosophy, Doctor of Science, EASL, Congress, University, Therapy, FRCP, SAN, Division, Abstract, MBBS, MRCP, Hepatology

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.
  • The abstracts released today can be found on the EASL website at www.easlcongress.eu .
  • Details from the abstracts released today are as follows:
    Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
    Presenter: Kosh Agarwal, MBBS, MRCP (UK), MD, FRCP (Ed), FRCP (London), Consultant Hepatologist and Transplant Physician, Institute of liver Studies, King’s College Hospital NHS Foundation Trust
    Abstracts identified as “Top” were selected as among the best in their category.
  • These posters will be displayed during the four days of the congress.

CVRx Announces Key Senior Leadership Team Hires

Retrieved on: 
Giovedì, Maggio 16, 2024
St. Thomas University, Patient, Divisional patent application, Employment, FACC, Heart failure, University, Nursing, Abbott Laboratories, FRCP, FESC, MBA, Senior, Circulatory system, RN, Policy, Normandale Community College, Concordia University, Guideline, Standard of care, Physiology, Health, Community college, Master of Science

Bonnie Handke will join as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics

Key Points: 
  • Bonnie Handke will join as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics
    MINNEAPOLIS, May 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced three additions to its senior leadership team.
  • "We are thrilled to welcome Dr. Adamson, Bonnie, and Jennifer to the CVRx leadership team.
  • These three executives will play an important role as we seek to move our Barostim therapy towards standard of care," said Kevin Hykes, President and CEO of CVRx.
  • Dr. Adamson joins CVRx from Abbott Laboratories, where he serves as Divisional Vice President and Chief Medical Officer of the Heart Failure division.

CDR-Life to Present at 6th Annual Cell Engager Summit

Retrieved on: 
Martedì, Maggio 21, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, CTA, Patient, Cancer, FRCP, Biting, Safety, City, Pharmaceutical industry

CDR-Life Inc. today announced that Chief Medical Officer Swethajit Biswas, MD, FRCP, will co-lead a seminar at the 6th Annual Cell Engager Summit, occurring May 21-23 in Boston.

Key Points: 
  • CDR-Life Inc. today announced that Chief Medical Officer Swethajit Biswas, MD, FRCP, will co-lead a seminar at the 6th Annual Cell Engager Summit, occurring May 21-23 in Boston.
  • The seminar, “ Back-Tracking Breakthroughs for BITEs & Cell Engagers to Gain Reverse Translation Insights ” will be co-led with Dr. Anthony Stein, MD, of City of Hope, and will delve into the practical implications of post-approval studies, shedding light on the long-term safety and efficacy of cell engager drugs.
  • By analyzing real-world data, researchers will gain valuable insights into overcoming the limitations of animal models and better replicating systemic immune responses in patients.
  • The seminar aims to foster actionable lessons for improving safety profiles and advancing the field of cell engager therapies.

Trevi Therapeutics to Participate in Upcoming Conferences

Retrieved on: 
Giovedì, Maggio 9, 2024
Corporation, Idiopathic pulmonary fibrosis, University, NIHR, NHS foundation trust, IPF, Respiratory Medicine, Doctor of Philosophy, MB, Chronic cough, University of Manchester, Panel, RCC, FRCP, Therapy, Management

Corporate Presentation: May 14 at 12:00 p.m.

Key Points: 
  • Corporate Presentation: May 14 at 12:00 p.m.
  • ET
    Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
  • Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice.

ACELYRIN, INC. Announces Leadership Transition

Retrieved on: 
Giovedì, Maggio 9, 2024
Corporation, Sale, Zymergen, Graves' ophthalmopathy, Immunotherapy, History, Administration, MRCP, Corporate development, IPO, Patient, Synthetic biology, LOS, SLRN, FRCP, Renewable energy, INC, Knowledge, Aviation, Management

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that ACELYRIN’s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, chief legal and administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company’s Board of Directors (the “Board”).

Key Points: 
  • Ms. Kim brings more than 20 years of operational and leadership experience across a range of industries including synthetic biology, immunotherapy, renewable energy, and aviation.
  • Ms. Kim played a pivotal role in ACELYRIN’s initial public offering and has served as ACELYRIN’s Chief Legal and Administrative Officer since November 2022.
  • “With encouraging data across our pipeline, we are continuing to advance our core mission of making a meaningful difference for patients.
  • The company will file the related quarterly report on Form 10-Q no later than May 14, 2024.

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
Giovedì, Maggio 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Retrieved on: 
Lunedì, Maggio 6, 2024
Duke University Hospital, University, T1D, MACP, SAB, NIH, University of Miami, Psychology, Immunotherapy, Thomas Jefferson University, Research, Immunomodulation, NIDDK, Metabolism, Pediatrics, Pennsylvania State University, FRCP, Internal medicine, Division, Pharmaceutical industry

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.

Key Points: 
  • MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.
  • “Dr.
  • Skyler’s appointment to our Board of Directors is a major milestone for SAB,” said Samuel J. Reich, SAB’s chairman and Chief Executive Officer.
  • “His deep expertise in type 1 diabetes research and leadership in the field will provide insights that will be invaluable to our SAB-142 program.